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Abstract
Microbubbles are widely used as contrast agents to improve the diagnostic capability of
conventional, highly speckled, low-contrast ultrasound imaging. However, while microbubbles can
be used for molecular imaging, these agents are limited to the vascular space due to their large size
(> 1 μm). Smaller microbubbles are desired but their ultrasound visualization is limited due to
lower echogenicity or higher resonant frequencies. Here we present nanometer scale, phase
changing, blinking nanocapsules (BLInCs), which can be repeatedly optically triggered to provide
transient contrast and enable background-free ultrasound imaging. In response to irradiation by
near-infrared laser pulses, the BLInCs undergo cycles of rapid vaporization followed by
recondensation into their native liquid state at body temperature. High frame rate ultrasound
imaging measures the dynamic echogenicity changes associated with these controllable, periodic
phase transitions. Using a newly developed image processing algorithm, the blinking particles are
distinguished from tissue, providing a background-free image of the BLInCs while the underlying
B-mode ultrasound image is used as an anatomical reference of the tissue. We demonstrate the
function of BLInCs and the associated imaging technique in a tissue-mimicking phantom and in vivo
for the identification of the sentinel lymph node. Our studies indicate that BLInCs may become a
powerful tool to identify biological targets using a conventional ultrasound imaging system.
Key words: Microbubbles, ultrasound imaging

Introduction
Ultrasound contrast agents provide acoustic
backscatter due to a mismatch in impedance between
the gas core of microbubbles and the surrounding,
water-based soft tissue. Contrast is also enhanced due
to compressibility of their gaseous cores compared to
surrounding tissues, resulting in mechanical
oscillations of the bubbles. Signal enhancement from
microbubbles was first demonstrated using
echocardiography in 1968.(1) Since then, a variety of
microbubbles and molecular targeting strategies have
been explored to assist in the identification of early
disease states.(2) However, despite the echogenicity of
microbubbles against a soft tissue background, the

local image contrast is hindered by the abundant
sub-wavelength acoustic scatterers in most biological
tissues.(3–5) To combat this issue, several functional
contrast agents and nonlinear imaging techniques
have been implemented. For example, harmonic and
pulse inversion imaging utilize the nonlinear
oscillatory behavior of microbubbles in response to
ultrasound irradiation, which can help distinguish
them from the background tissue.(6,7) However, the
harmonic response of tissues limits the specificity of
this technique, and tissue motion degrades the
detection of microbubbles.(8–10) Additionally,
microbubbles are confined to the vascular space due
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to their large size,(11) and their circulation time is
limited to a few minutes as gas diffuses from the
bubble core.(12)
A new generation of nano-sized triggerable
particles, referred to as phase-change nanodroplets, is
emerging to address these limitations. These stable
liquid droplets vaporize in response to either a pulsed
laser or ultrasound, providing contrast enhancement
activated by an external trigger.(13–17) When droplets
are vaporized using a pulsed laser, they
simultaneously emit a strong photoacoustic signal,
facilitating multimodal imaging.(13,14,18) Their small
size enables access to extravascular targets, and their
liquid core results in a more stable particle (hours)
(Supplementary
Information,
Fig.
S1)
than
conventional microbubbles.(12) Several groups have
previously developed perfluorocarbon (PFC) droplet
nanoemulsions for imaging and therapeutic
applications. Work by Sheeran et al. reports well
characterized, acoustically activatable PFC emulsions
for ultrasound and pulse inversion imaging
applications.(19) Rapoport et al. have encapsulated
therapeutics for a highly stable particle capable of
simultaneous imaging and ultrasound-triggered drug
delivery.(20) Other groups have encapsulated
photoabsorbers for optical activation. Wilson et al.
first reported laser-induced droplet vaporization for
simultaneous
ultrasound
and
photoacoustic
imaging.(14) Strohm et al. reported similar results
using droplets with incorporated quantum dots
activated by 1064 nm light for improved
photoacoustic contrast.(15) Akers et al. used a high
boiling point PFC with encapsulated dye for a stable
particle
capable
of
extended
photoacoustic
contrast.(21) Larson-Smith et al. report the
well-studied synthesis of a gold-nanoparticle
stabilized nanoemulsion.(22) To enable extended
imaging, several groups have used higher boiling
point PFC particles capable of repeated vaporization.
Rapoport et al. demonstrated repeated ultrasonic
activation of a highly stable particle.(20) Asami et al.
incorporated a dye into a high boiling point PFC
droplet and vaporized it repeatedly for prolonged
photoacoustic contrast.(23) Arnal et al. report the
synthesis of a gold particle shelled PFC emulsion and
a high contrast, real-time ultrasound/photoacoustic
imaging technique using synchronized laser
pulses.(24,25) Each of these strategies utilizes a
combination of particle properties, laser energy,
optical triggering, and ultrasound imaging techniques
to obtain high contrast biomedical image information.
This work aims to improve image contrast, depth
sensitivity, and particle stability to enhance diagnostic
information.

1867
Here we report stable, dynamic contrast agents
called BLInCs, which respond to optical irradiation
for a background-free, ultrasound-based image of the
particles. The BLInCs consist of a liquid
perfluorohexane (PFH) core, which has a bulk boiling
point of 56°C, resulting in a stable liquid droplet at
physiological temperatures (Fig. 1a). The submicron
BLInCs are encapsulated by a fluorosurfactant
polymer shell, which lowers the interfacial surface
tension.(26) The high curvature of the interface
increases the Laplace pressure between the PFH core
and the surrounding water, further stabilizing the
particles in a nano-sized state.(27) The BLInCs
incorporate a near-infrared absorbing dye and can be
activated by irradiating them with a pulsed laser. In
response to irradiation (Fig. 1a), the dye catalyzes
rapid (< 1-2 µs) droplet vaporization (Fig. 1b-c),
behavior observed in other PFC particles.(13–15) The
resulting transient gaseous microbubbles (Fig. 1c),
which persist for up to several milliseconds, reflect
ultrasound waves before recondensing back into their
stable, weakly scattering nanodroplet form (Fig. 1d).
This two-part phase change (liquid  gas  liquid)
“blinking” process can be measured (Fig. 1e) using
any clinical ultrasound imaging system capable of
high speed imaging techniques, such as ultrafast or
parallel beam imaging. The BLInCs can be activated
repeatedly by a series of laser pulses, inducing brief
moments of high echogenicity during their gaseous
phase. When imaged, this behavior differentiates
them from tissue, and the data can be processed to
form a background-free image of the BLInCs. When
combined with their size, the controllable dynamics of
the BLInCs may enable a wide array of high contrast
molecular ultrasound imaging and therapeutic
applications.

Materials and Methods
Synthesis of BLInCs
First, 1 mg of Epolight 3072 dye (Epolin, Inc.)
was added to 300 µL of PFH (FluoroMed, L.P.) and
dissolved by sonication at 180 W for 30 s in a VWR
benchtop ultrasonic cleaner. Then 1 mL of 1% v/v
aqueous Zonyl FSO fluorosurfactant (Sigma) and 1.7
mL of deionized water were added to the PFH. The
mixture was emulsified by vortexing for 10s and
sonicated for 2 minutes at 180 W in a VWR benchtop
ultrasonic cleaner. The nanodroplets were washed of
excess dye and fluorosurfactant by centrifuging at
1000 rcf for 5 minutes and replacing the supernatant
with deionized water. The BLInCs were diluted and
then manually counted under a light microscope to
obtain an estimate of their concentration after
synthesis.
http://www.thno.org
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Figure 1. (a) The BLInCs comprise a liquid PFH core with an encapsulated near-infrared dye stabilized by a surfactant shell. The particles are activated using a pulsed
laser. In their native state (b), the liquid BLInCs are weakly scattering and largely undetectable by ultrasound. Upon activation (c), the BLInCs undergo a rapid liquid-gas
phase change, rendering them temporarily hyperechoic. The BLInCs recondense back to their native liquid state (d), able to be activated again. (e) Pulse-echo
ultrasound image intensity from the periodic, laser-induced two-part phase changes.

Characterization of dye’s optical absorption
and BLInCs’ size
A small amount of the dye was dissolved in
chloroform and its extinction spectrum was measured
with a UV-3600 UV-Vis spectrometer (Shimadzu). A
Zetasizer Nano ZS system (Malvern Instruments Ltd.)
was used to measure the diameters of a 1% v/v
solution of as-prepared BLInCs, at 15 measurements
per run. An intensity-weighted distribution is
reported.

Optical verification of BLInC phase change
behavior
A DMI 3000B inverted light microscope
microscope (Leica Microsystems) was used to observe
a 0.01% v/v solution of perfluoropentane droplets. A
50 mJ/cm2 pulsed laser irradiated the sample to form
stable bubbles, and another image was collected
several minutes later. The temperature of the bubbles
was reduced to induce bubble recondensation.
Approximately 1 minute later, a final image of the
liquid droplets was collected.

Synthesis of Phantoms Containing BLInCs
Two types of phantoms were constructed: one
with a uniform distribution of BLInCs, and another
consisting of a BLInC-labeled cylindrical inclusion
within a BLInC-free background. To construct the
phantoms, 64 mL of water was mixed with 21 mL of
40% acrylamide (Ambion) and 850 μL of 438 mM
aqueous ammonium persulfate (Sigma-Aldrich). The

solution was stirred in a Büchner flask with a rubber
stopper to seal the top, and a tube connected to the
side attached to a vacuum. The solution was sonicated
under vacuum for 5 minutes to remove dissolved gas,
and then the vacuum was removed to stir in
additional components, using one of two
formulations listed below.
Phantom with uniform incorporation of BLInCs:
A solution of as-prepared, 180 nm diameter BLInCs
was added to the solution so that the entire phantom
contained 0.1% or 0.001% v/v of the as-prepared
BLInCs
solution.
Next,
106
μL
of
tetramethylethylene-diamine (TEMED) (Sigma) was
added. The entire solution was quickly poured into a
rectangular mold and allowed to polymerize for 10
minutes.
Phantom containing BLInC-labeled cylindrical
inclusion within BLInC-free background: 5 μm
Min-U-Sil silica particles (U.S. Silica) were added at
0.2% w/w, and graphite particles (Dixon) were added
at 0.01% w/w to mimic the optical absorption (2-3
cm-1) and acoustic scattering (1-2 dB MHz-1) of
biological tissue.(28,29) Next, 106 μL of TEMED was
added. The solution was quickly poured into a
rectangular mold, where a 1.2 mm diameter sealed
glass tube was positioned to create a cylindrical void
in the phantom. After polymerizing, another solution
was prepared which included 0.1% v/v of 180 nm
diameter BLInCs and excluded graphite particles. The
solution was poured into the cylindrical cavity, and
allowed to polymerize. The final concentration of
BLInCs in the inclusion was approximately 108/mL.
http://www.thno.org
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Imaging of BLInCs in Phantom
Each phantom was placed under a 40 MHz
imaging probe connected to a Vevo 2100 ultrasound
imaging system. The imaging probe and phantom
surface were coupled using clear ultrasound gel.
Optical fiber bundles were used to deliver 1064 nm
pulsed laser light from a Phocus Mobile laser system
(Opotek Inc.) to the phantom. Ultrasound B-mode
data was collected while the phantom was irradiated
with 5 ns laser pulses at a rate of 10 Hz. Image data
from 1000 frames over a period of ~3.5 seconds were
collected. For the phantoms with uniformly
distributed BLInCs, the laser fluence was varied from
5 to 20 mJ/cm2, with a frame rate of either 380 or 650
frames/second. The ultrasound window was 3.08 mm
wide, 15 mm deep with a 1 mm offset, and a 10 mm
focal depth. For the phantom with a cylindrical
inclusion, the laser fluence was 50 mJ/cm2, the frame
rate was 580 frames/second, and the ultrasound
window was 4.08 mm wide, 15 mm deep with a 1 mm
offset, with a focal depth of 13 mm. For the phantom
with the inclusion, the estimated fluence at the depth
of the inclusion was 6-12 mJ cm-2.
To visualize a three-dimensional volume, 21
image slices were collected 160 μm apart for a total
elevational distance of 3.2 mm. At each location, a set
of 1000 frames was acquired. The 2D or 3D IQ B-mode
data was obtained for processing, and linear image
intensity was calculated by (I2 + Q2)1/2. The image data
were further analyzed by custom-designed MATLAB
functions and routines. Three-dimensional images
were created using Amira (FEI Visualization Sciences
Group).

Formation of Background-Free Ultrasound
Image of BLInCs
To identify the location of the BLInCs in an
otherwise low contrast ultrasound image, a set of
B-mode ultrasound images was analyzed. This
technique utilizes the transmission of multiple US
waves, followed by subtraction of subsequent
received signals, similar to that used in pulse
inversion imaging.(6) Positive values of the
differential intensity denote increases in echogenicity
from vaporization, and negative spikes correspond to
recondensation of the bubbles into droplets. Pixels not
containing BLInCs, even though equally irradiated by
the laser light, did not exhibit these changes. To form
a map of the particles, two separate images were first
constructed. The first image was formed by
calculating a mean of the absolute value of the
difference values at frames corresponding to
activation by the laser. To make the second image, a
temporal autocorrelation of the absolute value of the
differential ultrasound intensity was calculated. Next,
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the ratio of the two greatest values of the
autocorrelation was calculated, using a delay
corresponding to the 10 Hz laser repetition rate. The
value of this ratio was then converted to image
intensity. The final image was created by pixel-wise
multiplication of the two previously formed images.
This map of BLInCs was then overlaid onto a B-mode
image. A more detailed description of the formation
of a background-free image can be found in the
Supplementary Information. Contrast and contrast-tonoise ratio were calculated using previously reported
methods (18).

Ultrasound Imaging of Lymph Node
All animal studies were performed under
protocols approved by the Institutional Animal Care
and Use Committee at The University of Texas at
Austin.
A previously developed mouse model of lymph
node drainage was used (30–32) in which a nude
Nu/Nu mouse (Charles River Laboratories) was
injected submucosally in the tongue with BLInCs.
Prior to injection, the mouse was anesthetized with a
combination of isoflurane (1.5%) and O2 (2 L/min). A
30-gauge needle was used to inject 40 µL of
as-prepared BLInCs over the course of approximately
10 s. The BLInCs were allowed to drain for 30 minutes
at which point ultrasound imaging was performed on
the cervical lymph nodes located in the mouse’s neck.
Clear ultrasound gel was used for acoustic coupling
between the transducer to the mouse. Ultrasound
images were acquired with a Vevo 2100
(VisualSonics) using a 40-MHz linear array transducer
(MS-550) at a rate of 618 frames/second. Light with a
wavelength of 1064 nm was generated by a Vibrant
Nd:YAG laser (Opotek) operating at 10 Hz and
coupled to a custom fiber bundle. The optical fluence
of approximately 50 mJ/cm2 irradiating the mouse
was well below the safety limit of 100 mJ/cm2 for
human skin exposure established by the American
National Standards Institute.(33) The ultrasound
window was 4.08 mm wide, 15 mm deep with a 4 mm
offset, and a focal depth of 9 mm. Immediately
following the imaging, the mouse was euthanized via
an overdose of isoflurane (5%) and cervical
dislocation.

Results
Photographs of the dye dissolved in chloroform,
a solution of blank droplets, and a solution of BLInCs
indicate the presence of the dye in the droplet solution
(Fig. 2a). The extinction spectrum of the dye exhibits
peak absorption in the near-infrared range (Fig. 2b). A
histogram of droplet diameters indicates their
submicron size (Fig. 2c).
http://www.thno.org
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Figure 2. (a) Photographs of the (left) encapsulated dye, (middle) blank perfluorocarbon droplets, and (right) BLInCs. (b) Optical extinction spectrum of the
encapsulated near-infrared absorbing dye. (c) Distribution of particle sizes.

Figure 3. Light microscope images of BLInCs (a) before activation, (b) after activation, and (c) after recondensation into a liquid state. Scale bar = 20 μm.

Microscope images of the droplets before (Fig.
3a) and after (Fig. 3b) irradiation confirm an increase
in particle diameter after vaporization, which is
concurrent with other studies indicating a 5x increase
in diameter.(15,34) Following recondensation, the
droplets reverted to their original size (Fig. 3c).
The changes in echogenicity of a phantom (0.1%
v/v BLInCs) exposed to various laser fluences
demonstrate the importance of selecting proper laser
energy. Perfluorohexane has a boiling point of 56° C,
and the Laplace pressure of nano-sized droplets
further stabilizes the BLInCs in a liquid state at
physiological temperatures. When the BLInCs were
irradiated below their vaporization threshold, they
failed to exhibit any measurable changes in
ultrasound echogenicity (Fig. 4a, black and Fig. 4b),
and the background-free imaging technique was
ineffective. When irradiated with sufficient energy,
the BLInCs underwent rapid liquid-gas vaporization
phase changes, followed immediately by gas-liquid
condensation, resulting in brief increases in
ultrasound signal from acoustic reflections by the
bubbles (Fig. 4a, blue). However, identifying these
momentary changes from the ultrasound images is
difficult (Fig. 4c). When irradiated with much higher
energy, the BLInCs underwent irreversible liquid-gas
vaporization and exhibited a stable increase in
ultrasound signal (Fig. 4a, red). While this provided
lasting increase in echogenicity (Fig. 4d), a lack of

‘blinking’ behavior renders the image processing
technique ineffective to suppress the background
signal and provide a high contrast map of the BLInCs.
The two-part phase change of BLInCs was
demonstrated using ultrasound imaging (650
frames/second) of a phantom with uniformly
distributed BLInCs at a concentration of 0.001% v/v.
The initially weakly scattering BLInCs (Fig. 5a)
temporarily appear as bubbles (Fig. 5b) upon
activation before recondensing back into their liquid
state (Fig. 5c). While easy to see in a non-scattering
phantom, the normal acoustic scattering of biological
tissues disguises the phase change, especially at low
BLInC concentrations.
Images of a phantom with a cylindrical inclusion
show the contrast enhancement by the BLInCs in an
environment that mimics the optical absorption and
acoustic scattering of biological tissues.(35) The
contrast of the BLInCs against an acoustic scattering
background is not high using conventional
ultrasound imaging techniques (contrast = 0.76,
contrast-to-noise ratio = -0.73 dB) (Fig. 6a). However,
a measurement of the ultrasound signal over time
shows that pixels within the inclusion undergo
reversible phase changes, while pixels in the
background are unaffected by laser pulses (Fig. 6b).
Difference images enhance the signal from the
blinking particles while suppressing the constant
background (Fig. 6c), because the derivative of an
http://www.thno.org
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unchanging signal is close to zero (Fig. 6d). While it
was most common for the ultrasound signal to exhibit
changes in the positive direction (BLInCs underwent a
liquid-gas-liquid phase change), some pixels
exhibited negative changes. This may have resulted
from moving bubbles, or a reverse phase changed
induced by positive pressure of the vaporized BLInCs
nearby. For this reason, an absolute value of the
derivative signal was used to capture a phase change
in either direction. Further enhancement of the signal
(Fig. 6e) was achieved using the autocorrelation of the
derivative (Fig. 6f). This resulted in a large value at
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delay = 0 for pixels both inside and outside of the
inclusion, but also yielded high values for delays at
intervals equal to the pulse repetition frequency of the
laser. By applying the image processing described in
the Materials and Methods section, a high contrast
map of the particles was constructed and overlaid
onto an ultrasound background for anatomical
reference. The image quality was greatly improved,
and the location of the BLInCs was identified more
easily (contrast = 2.8, contrast-to-noise ratio = 25 dB)
(Fig. 6g).

Figure 4. (a) Linear ultrasound signal from an image pixel of a phantom containing BLInCs irradiated with 5 mJ/cm2 (black), 8 mJ/cm2 (blue), and 20 mJ/cm2 (red).
Ultrasound images before and after irradiation at (b) 5, (c) 8, and (d) 20 mJ/cm2. Scale bars = 1 mm.

Figure 5. Ultrasound images of BLInCs (a) before activation, (b) after activation, and (c) after recondensation into a liquid state. Scale bar = 1 mm.

http://www.thno.org
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Figure 6. (a) Ultrasound image of a cross-section of a phantom with inclusion of BLInCs. (b) Linear ultrasound signal as a function of time for two pixels, one within
the inclusion of BLInCs, and one in the background. (c) Image formed by subtracting an ultrasound image frame before particle activation from an image frame after
particle activation. (d) Differential ultrasound signal as a function of time for the two featured pixels. (e) Image formed by processing to enhance the BLInCs and
suppress the background. (f) Autocorrelation of the differential ultrasound signal for the two pixels. (g) Background-free map of the BLInCs (green) overlaid onto the
ultrasound image of the phantom. Scale bar = 1 mm.

Figure 7. (a) Three-dimensional rendering of a series of B-mode ultrasound images of a phantom. (b) Three-dimensional rendering of the BLInCs signal after
processing the ultrasound image data to distinguish BLInCs from the background. Scale bar = 2 mm.

A 3-dimensional map of the BLInCs was
obtained by collecting and processing image data
along several elevational planes. Figure 7a is an
ultrasound 3D rendering of the phantom with the
cylindrical inclusion of BLInCs. While some
boundaries can be identified, the overall structure of
the inclusion is difficult to discern. By applying the
background-free imaging technique, the location of
BLInCs was identified more clearly while suppressing
the background signal of optical absorbers and
acoustic scatterers (Fig. 7b). Identifying BLInCs in a
biological environment with high sensitivity and
contrast using could enable early detection of various
disease markers.
In many types of cancer, identifying the sentinel
lymph node (SLN) is critical for accurate staging,

because it is the first lymph node to which
metastasized cells drain from a tumor. A mouse
model of lymphatic drainage demonstrates the utility
of BLInCs in SLN mapping.(32) Although ultrasound
imaging is routinely used for lymph node imaging,
the SLN cannot be accurately identified from anatomy
alone. Therefore, contrast agents are helpful in
mapping the SLN. As in the phantom imaging, laser
pulses were used to repeatedly activate the BLInCs.
However, the changes in echogenicity were difficult
to detect in real time (Fig. 8a-b) due to the low
concentration of bubbles, the highly scattering
background, the rapid recondensation of the BLInCs
into their liquid state, and the dB scale of ultrasound
images. The lymph node was roughly identified using
anatomical reference from the conventional B-mode
http://www.thno.org
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images (Fig. 8b). Using the time-series data, the rapid,
periodic changes in echogenicity distinguished the
BLInCs from the background by processing the
temporal characteristics of individual image pixels.
This resulted in a background-free map of the BLInCs,
which was overlaid onto an ultrasound image to
visualize them in an anatomical reference (Fig. 8c).
Here the BLInCs are seen throughout the volume of
the lymph node, indicating rapid drainage via the
lymphatic system, behavior that has been previously
observed and reported for similarly sized
particles.(36) Blinking signal was not observed in mice
where there was no injection of BLInCs
(Supplementary Fig. S6). The stability of
perfluorohexane droplets in vitro (37) and
perfluoropentane droplets in vivo (20) suggest that
BLInCs can circulate through the vasculature for
several hours. Prolonged imaging may be conducted
due to the sensitivity of the imaging procedure and
the ability of the BLInCs to undergo repeatable
activation, which would allow sufficient time for their
accumulation into extravascular tissues and/or
attachment to molecular targets. Significant blinking
signal appears at the surface of the skin. This is most
likely due to bubbles at the skin/gel interface, which
oscillate in the presence of photoacoustic signal
generation following laser irradiation. This oscillation
appears as blinking signal, so surface bubbles should
be minimized during this imaging process.

Discussion
The BLInCs facilitate a new imaging technique
for background-free images of injected particles.
However, the activation laser energy must be
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appropriate to allow for transient droplet
vaporization, accounting for optical absorption and
scattering in biological tissues. The laser fluence
required for vaporization in a non-scattering phantom
(Fig. 4, 5) was lower than that in a phantom
containing optical absorbers (Fig. 6, 7) or in a mouse
lymph node (Fig. 8). Given the optical wavelength of
activation and sensitivity of BLInCs to vaporization, it
is feasible that they may be imaged at depths of > 2
cm. (38)
To achieve both particle stability over time as
well as high contrast from their unique blinking
behavior, it is important activate BLInCs with a laser
fluence that achieves repeatable, reversible phase
changes. This is most easily accomplished by imaging
initially at low laser fluence, and then increasing the
energy until the blinking behavior can be observed.
Implementing a real-time imaging algorithm would
aid in selecting appropriate laser fluence.
The irreversible vaporization of BLInCs (Fig. 4d)
is possibly due to vaporization of larger BLInCs,
coalescence of neighboring bubbles into larger stable
bubbles, or diffusion of air into the cavity created by
the bubble. Larger bubbles are less prone to
recondense back into their liquid droplet form than
very small bubbles.(27) However, smaller BLInCs
require more laser energy to vaporize.(39–41) It is
desirable to synthesize a monodisperse sample of
droplets so that precise control over laser energy can
maximize the vaporization efficiency and prevent
irreversible vaporization. Stable bubble formation is
ineffective for producing a background-free image,
and the acoustic scattering from bubbles may mask
any blinking behavior from smaller BLInCs.

Figure 8. Ultrasound images of mouse tissue (a) before and (b) after optical irradiation, with a rough outline of the lymph node location. (c) The BLInCs signal,
overlaid onto the ultrasound image, shows the location of the particles, which have accumulated in the node of the lymphatic system. Scale bar = 1 mm.

http://www.thno.org
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To construct a background-free image, the
ultrasound image data was collected at a frame rate
high enough to capture the rapid two-stage phase
change of the BLInCs. The speed of the phase change
(most notably recondensation) depends on several
factors, including the size of the BLInCs and the
likelihood of neighboring bubble coalescence
following vaporization.(27) The likelihood of
coalescence depends on the concentration of bubbles
formed (either from a high concentration of BLInCs or
from efficient vaporization by high laser fluence).
Other factors may also affect speed of condensation,
such as the stiffness of the surrounding medium and
the ultrasound pressure field. It may be possible to
characterize tissue properties by observing the
dynamic behavior of the BLInCs in response to laser
activation.
While more than ten laser pulses were used to
form each of the images, this technique may be carried
out using fewer laser pulses. If the autocorrelation or a
similar approach is used to identify blinking pixels, at
least two laser pulses are required, although greater
image contrast will result when more phase changes
are measured. The laser pulse repetition frequency
determines the imaging frame rate, thus higher frame
rate can be achieved by using lasers with much faster
pulse repetition frequency.
Most pixel data of BLInCs exhibited an increase
in echogenicity followed by a decrease in echogenicity
at intervals corresponding to laser pulses. However,
some pixels underwent a decrease in echogenicity
followed by an increase, the opposite of what was
expected. These data are possibly indicative of
bubbles that moved while other BLInCs were being
activated, or to surrounding pressure increases which
induced bubble recondensation. To overcome this
limitation, the absolute value of the difference image
was used during formation of the background-free
image.
Droplet vaporization has also been triggered
with high intensity focused ultrasound (HIFU),
(17,42) which could also be used to trigger BLInCs
without a laser or optical absorber. However, due to
the high boiling point of perfluorohexane,
vaporization with HIFU may require intensity levels
of up to 1,000 W/cm2,(43) which is 500 times the safe
recognized
level
for
peripheral
tissue,(44)
compromising the safety of the imaging technique.
Some research exists showing that the vaporization
threshold of perfluorocarbon droplets can be reduced
by incorporating nucleation seeds,(45,46) which may
enable deeper, more sensitive activation of BLInCs.
The transient phase-change behavior of BLInCs
makes them a valuable tool for high contrast
biomedical imaging. Any injectable particles,
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however, must be made of materials approved for
human use before clinical translation. While the
BLInCs reported here encapsulate a near-infrared dye
for improved optical penetration in tissue at 1064
nm,(47) similar particles have been made using
clinically approved indocyanine green dye.(13) Thus
it is feasible to synthesize BLInCs out of entirely
approved materials to be used in a clinical setting.
BLInCs may be used as a therapeutic tool in
addition to their high contrast imaging utility.
Localized drug delivery could be achieved with these
or similar triggerable nanodroplets, whereby drug is
released upon activation of the particle and delivery
to the site of interest is improved through nanodroplet
extravasation, or intracellular droplet or drug uptake
through sonoporation.(48,49) It is possible that the
repeatable vaporization may provide sustained
therapeutic benefit similar to the effects of
microbubble-assisted HIFU therapy, which is
unattainable through irreversible optical droplet
vaporization alone. Additionally, imaging the BLInCs
could identify the site of therapeutic payload.

Conclusion
The BLInCs introduced here facilitate a new
technique
for
background-free
imaging
of
nanoparticles using a conventional ultrasound
imaging system. Due to their stability and small size,
the droplets are capable of extended circulation time
and extravasation, a key component of imaging on the
molecular scale. The BLInCs are made to activate
through a unique, laser-induced rapid sequence of
two
phase
changes—vaporization
and
recondensation—which is processed into a
background-free map of the particles. This imaging
technique is highly sensitive to diluted particles. Due
to their blinking behavior, individual BLInCs can be
located among the vast acoustic scatterers present in
tissue. These experiments identify BLInCs with high
specificity and sensitivity in the optically absorbing
and acoustically scattering background of a living
mouse. Furthermore, cell-specific targeting has been
achieved with similar perfluorocarbon microbubbles
by conjugating various molecules to the particle
shell.(50–53) The smaller size and enhanced
circulation time of nanodroplets make them a feasible
candidate for molecular imaging, expanding the
performance of this nanoparticle-based ultrasound
imaging platform.
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